Advances in the Testing and Treatment of Alzheimer’s Disease

Jeffrey L. Cummings, MD, ScD, explains the pathophysiology and common screening tools used to evaluate Alzheimer’s disease.

Jeffrey L. Cummings, MD, ScD, discusses the biomarker assessments used to test for amyloid beta that can confirm disease pathology for Alzheimer’s disease.

Jeffrey L. Cummings, MD, ScD, delves into the biomarker assessments that establish a diagnosis of Alzheimer’s disease and their use in clinical practice.

Jeffrey L. Cummings, MD, ScD, discusses the importance of aducanumab, a recently approved treatment for Alzheimer’s disease.

Dr Cummings relays how testing methods influence the treatment course for Alzheimer’s disease.

Jeffrey L. Cummings, MD, ScD, comments on the unmet needs and future outlook for the Alzheimer’s treatment landscape.